R&D Trends

J&J opens London innovation center

Wednesday, March 13, 2013 02:36 PM

Johnson & Johnson has opened the Johnson & Johnson Innovation center in London, one of four regional hubs being established this year in the world's leading innovation hotspots. A part of Johnson & Johnson Innovation, the goal of the London innovation center is to accelerate the best early stage science in the world and advance the development of new healthcare solutions.

More... »

Celtic Therapeutics rebrands as Auven Therapeutics

Wednesday, March 13, 2013 01:39 PM

Celtic Therapeutics Management, a global private equity company focused on acquiring novel, life-saving and quality of life-enhancing products and accelerating the development of these products, has changed its name to Auven Therapeutics Management.

More... »

Orion, Gedeon Richter ink novel CNS R&D collaboration agreement

Wednesday, March 13, 2013 11:37 AM

Orion, a Finnish pharmaceutical company, and Gedeon Richter, a Hungarian pharmaceutical company, have entered into a comprehensive and long term collaboration agreement for the discovery and development of new chemical entities in the field of cognitive disorders.

More... »

Astellas, Ambit terminate collaboration on FLT3 kinase inhibitors

Wednesday, March 13, 2013 10:39 AM

Tokyo-based Astellas Pharma and San Diego-based Ambit Biosciences will end their collaboration for the joint development and commercialization of FMS-like tyrosine kinase-3 (FLT3) inhibitors, including quizartinib, effective September 3, 2013.

More... »

Mayo, Sanford-Burnham extend collaborative agreement

Wednesday, March 13, 2013 10:10 AM

Sanford-Burnham Medical Research Institute and the Mayo Clinic signed a new collaborative agreement to build a pipeline of therapeutic drugs aimed at a variety of diseases with serious unmet medical needs.

More... »

Elsevier, ACC launch new journal JACC: Heart Failure

Monday, March 11, 2013 03:03 PM

Elsevier, a world-leading provider of scientific, technical and medical information products and services, and the American College of Cardiology (ACC) have launched a new journal named JACC: Heart Failure. This journal will better meet the demands and challenges of treating what is now the most rapidly increasing category of cardiac disease. The first publication is now available here.

More... »

Report: Biologics research promises to bolster future of medicine

Monday, March 11, 2013 02:01 PM

America's biopharmaceutical companies are using biological processes to develop 907 medicines and vaccines targeting more than 100 diseases, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA).

More... »

Progenitor Labs secures $5.8M to progress regenerative medicine platform

Monday, March 11, 2013 11:36 AM

Progenitor Labs, a regenerative medicine company, has raised $5.8 million in seed financing from the U.K. Fund of SR One, GlaxoSmithKline's independent corporate healthcare venture capital fund.

More... »

Galapagos and Roche conclude strategic alliance

Monday, March 11, 2013 10:38 AM

Galapagos, mid-size clinical stage biotechnology company, has agreed with Roche to end their alliance in fibrosis. Roche will make a payment of $975,000 to Galapagos for work completed in 2012, contributing to 2012 group revenues.

More... »

Janssen launches global cardiovascular research program, five new studies

Friday, March 8, 2013 10:47 AM

Janssen Research & Development has launched EXPLORER, a comprehensive, global research program for XARELTO (rivaroxaban), an oral anticoagulant. The program includes studies that will evaluate XARELTO for investigational use in patients with chronic heart failure and in those with coronary artery disease or peripheral artery disease.

More... »